HEMGENIX FUNDAMENTALS EXPLAINED

Quantity of suitable clients: CDEC reviewed the uncertainty in the quantity of clients with reasonably significant to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who are categorised as having moderate or reasonable illness may have a severe bleed